Published in Mov Disord on August 01, 2003
End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. J Neurol (2006) 0.78
Cabergoline versus levodopa monotherapy. Mov Disord (2004) 0.75
Re: Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord (2004) 0.75
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med (2009) 13.42
The effect of electronic prescribing on medication errors and adverse drug events: a systematic review. J Am Med Inform Assoc (2008) 4.77
The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ (2010) 3.95
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood (2012) 3.38
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol (2010) 2.89
Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci (2004) 2.84
The REM sleep behavior disorder screening questionnaire--a new diagnostic instrument. Mov Disord (2007) 2.64
Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care (2008) 2.64
Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke (2005) 2.29
Can we reliably benchmark health technology assessment organizations? Int J Technol Assess Health Care (2012) 2.27
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health (2012) 2.14
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005) 2.06
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer (2006) 2.04
Hyperalgesia and functional sensory loss in restless legs syndrome. Pain (2013) 2.00
Evidence for lower variability of coronary artery calcium mineral mass measurements by multi-detector computed tomography in a community-based cohort--consequences for progression studies. Eur J Radiol (2006) 1.99
Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation (2010) 1.92
Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology (2012) 1.89
Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol (2005) 1.88
Diagnostic performance of stress perfusion and delayed-enhancement MR imaging in patients with coronary artery disease. Radiology (2006) 1.85
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2008) 1.83
Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol (2008) 1.82
The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.78
Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol (2006) 1.77
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations? Int J Technol Assess Health Care (2010) 1.70
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health (2009) 1.62
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making (2012) 1.61
Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol (2011) 1.60
NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Exp Neurol (2008) 1.59
Mercury in breast milk - a health hazard for infants in gold mining areas? Int J Hyg Environ Health (2008) 1.58
Gene expression profiling of Lewy body-bearing neurons in Parkinson's disease. Exp Neurol (2005) 1.58
High-resolution MR imaging of human atherosclerotic femoral arteries in vivo: validation with intravascular ultrasound. J Vasc Interv Radiol (2003) 1.57
Cumulative cost pattern comparison of prostate cancer treatments. Cancer (2007) 1.57
Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology (2005) 1.57
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord (2005) 1.54
Impact of intravascular ultrasound-guided stenting on long-term clinical outcome: a meta-analysis of available studies comparing intravascular ultrasound-guided and angiographically guided stenting. Catheter Cardiovasc Interv (2003) 1.54
Postoperative troponin-T predicts prolonged intensive care unit length of stay following cardiac surgery. Crit Care Med (2004) 1.53
The Munich score: a clinical index to predict survival in ambulatory patients with chronic heart failure in the era of new medical therapies. J Heart Lung Transplant (2008) 1.51
Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes. Mov Disord (2012) 1.50
Impact of increased number of biopsies on the nature of prostate cancer identified. J Urol (2006) 1.50
Serum concentrations of s100b and NSE in migraine. Headache (2009) 1.48
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson's disease in children. J Hepatol (2007) 1.44
Cardiac magnetic resonance perfusion imaging for the functional assessment of coronary artery disease: a comparison with coronary angiography and fractional flow reserve. Eur Heart J (2006) 1.41
Memory for public events in patients with unilateral temporal lobe epilepsy. Epilepsy Behav (2010) 1.41
Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. Radiology (2005) 1.39
Education predicts quality of life among men with prostate cancer cared for in the Department of Veterans Affairs: a longitudinal quality of life analysis from CaPSURE. Cancer (2007) 1.37
Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain (2002) 1.37
A systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. J Card Fail (2006) 1.36
Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A (2009) 1.35
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord (2008) 1.33
Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci (2003) 1.30
Mercury as a serious health hazard for children in gold mining areas. Environ Res (2008) 1.30
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol (2007) 1.29
The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem (2005) 1.27
Cytokines and epilepsy. Seizure (2011) 1.26
Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. Nat Neurosci (2011) 1.24
Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations. Value Health (2008) 1.24
Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain (2003) 1.24
Long-term patency of internal mammary artery bypass grafts: relationship with preoperative severity of the native coronary artery stenosis. Circulation (2004) 1.24
A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. Eur J Radiol (2007) 1.21
The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord (2014) 1.20
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol (2007) 1.20
Timecourse of health-related quality of life as determined 3, 6 and 12 months after stroke. Relationship to neurological deficit, disability and depression. J Neurol (2002) 1.20
Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry. Circulation (2002) 1.19
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord (2010) 1.18
Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci (2007) 1.18
Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. Parkinsonism Relat Disord (2010) 1.16
Health assessment of artisanal gold miners in Tanzania. Sci Total Environ (2009) 1.16
Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care (2008) 1.16
Concepts of 'personalization' in personalized medicine: implications for economic evaluation. Pharmacoeconomics (2015) 1.16
Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem (2003) 1.15
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord (2011) 1.15
EBM, HTA, and CER: clearing the confusion. Milbank Q (2010) 1.15
Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord (2011) 1.14
Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics (2005) 1.13
RNA editing modulates the binding of drugs and highly unsaturated fatty acids to the open pore of Kv potassium channels. EMBO J (2010) 1.12
Health-related quality of life in patients with narcolepsy. Sleep Med (2007) 1.11
A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J (2006) 1.11
Rational therapeutic approaches to progressive supranuclear palsy. Brain (2010) 1.11
Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord (2005) 1.09
Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord (2007) 1.07
Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations. Med Decis Making (2009) 1.07
Lack of differences of motorcortical excitability in the morning as compared to the evening in juvenile myoclonic epilepsy--a study using transcranial magnetic stimulation. Epilepsy Res (2007) 1.07
Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report. Int J Technol Assess Health Care (2010) 1.06
Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practice. J Neurol (2009) 1.06
Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study. JACC Cardiovasc Interv (2011) 1.06